Eli Lilly and Company (NYSE:LLY) Trading 1.4% Higher

Eli Lilly and Company (NYSE:LLY) shot up 1.4% on Thursday . The company traded as high as $793.67 and last traded at $788.72. 933,417 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 3,196,724 shares. The stock had previously closed at $778.18.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Bank of America boosted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Truist Financial restated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. BMO Capital Markets upped their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $689.52.

Eli Lilly and Company Trading Down 0.0 %

The firm has a market cap of $739.19 billion, a P/E ratio of 134.56, a PEG ratio of 1.70 and a beta of 0.34. The company’s 50 day moving average is $730.97 and its two-hundred day moving average is $637.01. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the company earned $2.09 EPS. The company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the sale, the insider now owns 99,719,884 shares of the company’s stock, valued at approximately $63,004,019,910.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Fairfield Bush & CO. bought a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $107,000. Roundview Capital LLC raised its position in shares of Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after acquiring an additional 53 shares during the last quarter. Merit Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $210,000. NewEdge Advisors LLC increased its stake in shares of Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after acquiring an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $561,000. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.